Get the Stockscreener App
26.16
2.36%
0.724
Beam Therapeutics Inc stock is traded at $26.16, with a volume of 742.59K.
It is up +2.36% in the last 24 hours and down -5.72% over the past month.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.
See More
Previous Close:
$25.44
Open:
$25.33
24h Volume:
742.59K
Relative Volume:
0.37
Market Cap:
$2.66B
Revenue:
$139.74M
Net Income/Loss:
$-79.99M
P/E Ratio:
-25.76
EPS:
-1.0157
Net Cash Flow:
$-360.05M
1W Performance:
+5.60%
1M Performance:
-5.72%
6M Performance:
-6.57%
1Y Performance:
+59.07%
1-Day Range:
$25.20
$26.20
1-Week Range:
$23.44
$26.36
52-Week Range:
$13.98
$36.44
Beam Therapeutics Inc Stock (BEAM) Company Profile
Name
Beam Therapeutics Inc
Sector
Industry
Phone
857-327-8775
Address
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Compare BEAM vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BEAM
Beam Therapeutics Inc
|
26.11 | 2.59B | 139.74M | -79.99M | -360.05M | -1.0157 |
VRTX
Vertex Pharmaceuticals Inc
|
440.71 | 112.92B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
765.40 | 81.99B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
790.65 | 48.82B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
323.92 | 43.66B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
315.11 | 34.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Beam Therapeutics Inc Stock (BEAM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-20-26 | Initiated | Canaccord Genuity | Buy |
| Oct-09-25 | Initiated | Jefferies | Buy |
| Mar-28-25 | Upgrade | BofA Securities | Neutral → Buy |
| Mar-10-25 | Upgrade | Scotiabank | Sector Perform → Sector Outperform |
| Jan-29-25 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Nov-06-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Jul-23-24 | Initiated | H.C. Wainwright | Buy |
| Jan-29-24 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-15-23 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-08-23 | Downgrade | Jefferies | Buy → Hold |
| Oct-20-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Oct-20-23 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Mar-21-23 | Initiated | Bernstein | Mkt Perform |
| Feb-01-23 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-20-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-13-22 | Initiated | Citigroup | Buy |
| Jun-17-22 | Initiated | BMO Capital Markets | Market Perform |
| Apr-28-22 | Initiated | Credit Suisse | Neutral |
| Jan-05-22 | Initiated | Guggenheim | Buy |
| Oct-19-21 | Initiated | SVB Leerink | Outperform |
| Sep-24-21 | Resumed | Stifel | Buy |
| Sep-10-21 | Initiated | BofA Securities | Buy |
| May-11-21 | Initiated | Redburn | Buy |
| May-04-21 | Initiated | RBC Capital Mkts | Sector Perform |
| Mar-01-21 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-16-21 | Initiated | Wells Fargo | Overweight |
| Jan-29-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Jan-06-21 | Initiated | Stifel | Hold |
| Aug-05-20 | Initiated | William Blair | Outperform |
| Mar-02-20 | Initiated | Barclays | Overweight |
| Mar-02-20 | Initiated | JP Morgan | Overweight |
| Mar-02-20 | Initiated | Jefferies | Buy |
| Mar-02-20 | Initiated | Wedbush | Outperform |
View All
Beam Therapeutics Inc Stock (BEAM) Latest News
Beam Therapeutics President Sells $290,289 in Stock - National Today
(BEAM) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Global DNA Read, Write and Edit Market to Surge to $67.7 Billion by 2030, Driven by CRISPR Advances, Genomic Diagnostics and Expanding Clinical Applications - GlobeNewswire Inc.
Beam Therapeutics CEO Sells Over $700K in Stock - National Today
Beam Therapeutics Insider Sells $146K in Shares - National Today
JonesTrading Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Maintains Target Price $35 - Moomoo
Beam Therapeutics CEO Evans sells $739k in stock By Investing.com - Investing.com Australia
Amy Simon, Beam Therapeutics CMO, sells $164,686 in stock By Investing.com - Investing.com India
Beam Therapeutics (NASDAQ:BEAM) Insider Amy Simon Sells 6,700 Shares of Stock - MarketBeat
John Evans Sells 30,078 Shares of Beam Therapeutics (NASDAQ:BEAM) Stock - MarketBeat
Beam Therapeutics (NASDAQ:BEAM) Insider Christine Bellon Sells 5,956 Shares - MarketBeat
Bethany Cavanagh (Beam Therapeutics) sells $79,688 in BEAM stock By Investing.com - Investing.com Australia
Beam Therapeutics CEO Evans sells $739k in stock - Investing.com
Amy Simon, Beam Therapeutics CMO, sells $164,686 in stock - Investing.com
Beam Therapeutics president sells $290k in shares - Investing.com
[Form 4] Beam Therapeutics Inc. Insider Trading Activity - Stock Titan
Bethany Cavanagh (Beam Therapeutics) sells $79,688 in BEAM stock - Investing.com
Beam Therapeutics (BEAM) CMO covers tax obligations via 6,700-share sale - Stock Titan
Beam Therapeutics (BEAM) SVP auto-sells shares to cover RSU tax obligations - Stock Titan
Beam Therapeutics (BEAM) CLO auto-sells 5,956 shares for RSU tax withholding - Stock Titan
Beam Therapeutics (BEAM) president’s 11,810-share sale covers RSU taxes - Stock Titan
BEAM SEC FilingsBeam Therapeutics Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Beam Therapeutics Inc. (BEAM) Stock Price, News, Quote & History - Yahoo! Finance Canada
SG Americas Securities LLC Boosts Beam Therapeutics Stake by 139% - National Today
SG Americas Securities LLC Acquires 60,249 Shares of Beam Therapeutics Inc. $BEAM - MarketBeat
Beam Therapeutics Inc. (BEAM) stock price, news, quote and history - Yahoo Finance Australia
Intellia Therapeutics, Inc. (NTLA) Stock Price, News, Quote & History - Yahoo! Finance Canada
Beam Therapeutics Inc. (BEAM) interactive stock chart - sg.finance.yahoo.com
Beam Therapeutics (NASDAQ: BEAM) awards 20,000 RSUs to Chief Legal Officer - Stock Titan
Beam Therapeutics (BEAM) awards 20,000 RSUs to SVP Bethany Cavanagh - Stock Titan
Beam Therapeutics (BEAM) awards 31,750 RSUs to Chief Medical Officer Amy Simon - Stock Titan
CFO of Beam Therapeutics (NASDAQ: BEAM) awarded 31,750 RSUs - Stock Titan
Beam Therapeutics (BEAM) grants president 40,000 restricted stock units - Stock Titan
Beam Therapeutics (BEAM): Among the stocks that could 10x over the next 5 years - MSN
Insider Selling: Beam Therapeutics (NASDAQ:BEAM) CEO Sells 25,000 Shares of Stock - MarketBeat
Beam Therapeutics (BEAM): Among the Stocks That Could 10x Over the Next 5 Years - Yahoo Finance
Beam Therapeutics Insider Sold Shares Worth $1,128,315, According to a Recent SEC Filing - Moomoo
Beam Therapeutics shares climb after positive BEAM-302 trial update - MSN
BEAM Stock Price, Quote & Chart | BEAM THERAPEUTICS INC (NASDAQ:BEAM) - ChartMill
Beam (BEAM) Reports Promising Data from BEACON Trial in Sickle C - GuruFocus
Beam Therapeutics publishes sickle cell therapy trial data By Investing.com - Investing.com Australia
Why Is BEAM Stock Edging Higher After Hours Today? - Stocktwits
Beam Therapeutics CEO Evans sells $1.1m in stock By Investing.com - in.investing.com
Beam Therapeutics CEO Evans sells $1.1m in stock - Investing.com
Beam Therapeutics (BEAM) CEO sells 50K shares, gains 90K RSUs - Stock Titan
Beam Therapeutics publishes sickle cell therapy trial data - Investing.com
Beam Therapeutics Announces Publication of BEACON Phase 1/2 Data for risto-cel in Patients with Sickle Cell Disease (SCD) in The New England Journal of Medicine - The Manila Times
Beam Therapeutics Announces Publication of BEACON Phase 1/2 - GlobeNewswire
In 31 sickle cell patients, Beam saw no severe pain crises after risto-cel - Stock Titan
[144] Beam Therapeutics Inc. SEC Filing - Stock Titan
ETRADE Financial (NASDAQ: BEAM) insider sales and restricted vesting - Stock Titan
Beam Therapeutics Inc Stock (BEAM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.00%
1.95%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):